http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003068340-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
filingDate 2002-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fbe5aa6276ebd73a0a63056a81253a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50da861dd27c4568cb5ed56d1c73c6a
publicationDate 2003-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2003068340-A1
titleOfInvention Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
abstract Disclosed are formulations and compositions comprising, and process for preparing, improved parenteral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea. Also disclosed are methods of treating cytokine mediated diseases using such formulations and compositions.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11123349-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007203141-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7919617-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010093735-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7897599-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649268-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112218618-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010093734-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005107399-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7749999-B2
priorityDate 2001-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6254888-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6565880-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCD4A1A6
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO73909
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A3Q1MKE9
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486252
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE1BLE5
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCJ9P745
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCJ9NSP1
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14049689
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226499079
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE1BD32
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE2R8Z2
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128652222
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF1PT49
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412622
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE2R865
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID142526886
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426208976
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF6X1Q9
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCH0YYU7
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID156422
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF1MWT5
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582371
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCD4A9I5
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A0R4IYF1
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234

Total number of triples: 56.